IP Library Granted Patent US 8,529,901
Granted Patent B2
US 8,529,901 · App. 12/599,713 · Granted Sep 10, 2013

Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label

Inventors: Max Hasmann (Munich, DE); Helmut Lenz (Tutzing, DE); Werner Scheuer (Penzberg, DE)
Assignee: Hoffmann-La Roche, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,529,901
App. No.
12/599,713
Granted
Sep 10, 2013
Kind
B2
Abstract

This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

Claims (7)

1. A method for NIR fluorescence imaging of solid tumors during treatment with a non-labeled first antibody, said method comprising:

a) providing to the patient a first dose with a second monoclonal antibody labeled with a NIR fluorescence label, specifically binding to the same tumor antigen as the first monoclonal antibody, wherein the first and second monoclonal antibody exhibit no cross reactivity,

b) measuring the NIR fluorescence signal of said second monoclonal antibody labeled with a NIR fluorescence label in a region of the solid tumor,

c) providing to the patient a first dose with said non-labeled first monoclonal antibody,

d) providing to the patient a second dose with said second monoclonal antibody labeled with a NIR fluorescence label, and

e) measuring the NIR fluorescence signal of said second monoclonal antibody labeled with a NIR fluorescence label in said region of the solid tumor and determining whether said signal has decreased compared to the signal measured under “b”; wherein if said signal measured in step “e” is decreased by at least 10%, then providing to the patient a second dose of said non-labeled first monoclonal antibody.

2. The method according to claim 1 , wherein the signal/background ratio is at least 1.5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2010
From: HASMANN, MAX; LENZ, HELMUT; SCHEUER, WERNER
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 025302/0024 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2010
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE, INC.
Reel/Frame 025302/0027 →
Priority Claims (1)
EP 07011087 · Jun 6, 2007 · regional
Continuity (1)
Related Publication 20110027190A1 · Feb 3, 2011